Conversely, cervical cancer cell growth in vivo could be stopped by ETAR blockade with Atrasentan (ABT-627), a selective ETAR-inhibitor, alone, and in that study Atrasentan displayed additive antitumour effects when administered in combination with the cytotoxic agent Paclitaxel (Bagnato et al, 2002). Here, EDNRA is linked to cervical cancer.